Superworth

Foghorn Therapeutics EPS FHTX

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$0.98
Latest quarter, Q2 FY26
−$0.10
Fiscal year 2025
−$1.17

Foghorn Therapeutics' earnings per share was −$0.98 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.10.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.17n/a
FY2024−$1.66n/a
FY2023−$2.34n/a
FY2022−$2.62n/a
FY2021−$2.73n/a
FY2020−$9.48n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.10n/a−$0.98
Q1 FY26−$0.29n/a−$1.16
Q4 FY25−$0.34n/a−$1.17
Q3 FY25−$0.25n/a−$1.14
Q2 FY25−$0.28n/a−$1.20
Q1 FY25−$0.30n/a−$1.37
Q4 FY24−$0.31n/a−$1.66
Q3 FY24−$0.31n/a−$1.92
Q2 FY24−$0.45n/a−$1.95
Q1 FY24−$0.59n/a−$2.20
Q4 FY23−$0.57n/a−$2.34
Q3 FY23−$0.34n/a−$2.46

Against its peers

Companies in Drug Manufacturers - General nearest Foghorn Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
FHTXFoghorn Therapeutics−$0.98
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Foghorn Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.